Action Serono - SRA

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

Prix Achat

Prix Vente

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Merck Serono and Domain Therapeutics Announce an Agreement to Develop Drugs for Parkinson's Disease

Merck Serono and Domain Therapeutics Announce an Agreement to Develop Drugs for Parkinson's Disease - Merck Serono to Develop Domain...

Brighter Futures in MS - Inspiring Short Film Premieres in Brussels

Brighter Futures in MS - Inspiring Short Film Premieres in Brussels PR Newswire GENEVA and BRUSSELS, January 12, 2011 GENEVA and BRUSSELS...

Merck Serono and San Raffaele Scientific Institute to Collaborate on Research in Neurodegenerative Diseases

Merck Serono and San Raffaele Scientific Institute to Collaborate on Research in Neurodegenerative Diseases PR Newswire GENEVA, December 13, 2010...

Merck Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Mu

Merck Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Multiple...

Merck Serono: Enrollment Completed for ORACLE MS Study of Cladribine Tablets in Patients at Risk of Developing MS

Merck Serono: Enrollment Completed for ORACLE MS Study of Cladribine Tablets in Patients at Risk of Developing MS PR Newswire GENEVA, November...

Merck Serono: Ready-to-Use Formulation of Recombinant Growth Hormone Saizen Recommended for Approval in Europe

Merck Serono: Ready-to-Use Formulation of Recombinant Growth Hormone Saizen Recommended for Approval in Europe - Saizen(R) Solution For Injection...

Merck Serono Announces Top-Line Results of Long-Term Study of Safinamide as Add-on Treatment to Levodopa in Advanced Parkinson's

Merck Serono Announces Top-Line Results of Long-Term Study of Safinamide as Add-on Treatment to Levodopa in Advanced Parkinson's Disease PR...

Merck Serono Sells Théramex to Teva for EUR 265 Million

Merck Serono Sells Théramex to Teva for EUR 265 Million - Acquisition Will Provide Teva With a Strong Platform to Expand its Global Women's...

Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of

Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of the Disease...

Merck Serono to Introduce RebiDose(TM), the Rebif(R) Single Use Pre-filled Pen for Treatment of Multiple Sclerosis

Merck Serono to Introduce RebiDose(TM), the Rebif(R) Single Use Pre-filled Pen for Treatment of Multiple Sclerosis - RebiDose(TM) has Been...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

SRA - Frequently Asked Questions (FAQ)

What is the current Serono share price?

The current share price of Serono is US$ 0,00

What is the 1 year trading range for Serono share price?

Serono has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
CXMSprinklr Inc	US$ 9,10 (12,62%)	623,02k
MXMagnachip Semiconductor Corp	US$ 4,46 (10,40%)	188,59k
JEQabrdn Japan Equity Fund Inc	US$ 6,40 (9,22%)	189,31k
ENFYEnlightify Inc	US$ 1,19 (9,17%)	142
XPOFXponential Fitness Inc	US$ 12,505 (8,55%)	79,24k
DTCSolo Brands Inc	US$ 0,3925 (-40,08%)	823k
LDIloanDepot Inc	US$ 1,33 (-17,39%)	1,55M
FOAFinance of America Companies Inc	US$ 18,10 (-14,62%)	204,1k
MATVMativ Holdings Inc	US$ 5,93 (-13,68%)	387,08k
HRTGHeritage Insurance Holdings Inc	US$ 10,7775 (-9,28%)	116,94k
NIONIO Inc	US$ 5,315 (1,82%)	22,46M
BBAIBigBear ai Holdings Inc	US$ 3,295 (3,62%)	11,2M
QBTSD Wave Quantum Inc	US$ 5,43 (0,93%)	11,15M
TAT&T Inc	US$ 25,095 (-3,52%)	9,51M
VZVerizon Communications Inc	US$ 41,3525 (-4,78%)	8,45M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Serono S A (SRA)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

SRA Dernières nouvelles

Merck Serono and Domain Therapeutics Announce an Agreement to Develop Drugs for Parkinson's Disease

Brighter Futures in MS - Inspiring Short Film Premieres in Brussels

Merck Serono and San Raffaele Scientific Institute to Collaborate on Research in Neurodegenerative Diseases

Merck Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Mu

Merck Serono: Enrollment Completed for ORACLE MS Study of Cladribine Tablets in Patients at Risk of Developing MS

Merck Serono: Ready-to-Use Formulation of Recombinant Growth Hormone Saizen Recommended for Approval in Europe

Merck Serono Announces Top-Line Results of Long-Term Study of Safinamide as Add-on Treatment to Levodopa in Advanced Parkinson's

Merck Serono Sells Théramex to Teva for EUR 265 Million

Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of

Merck Serono to Introduce RebiDose(TM), the Rebif(R) Single Use Pre-filled Pen for Treatment of Multiple Sclerosis

SRA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Serono S A (SRA) Cours

Serono S A (SRA)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

SRA Dernières nouvelles

Merck Serono and Domain Therapeutics Announce an Agreement to Develop Drugs for Parkinson's Disease

Brighter Futures in MS - Inspiring Short Film Premieres in Brussels

Merck Serono and San Raffaele Scientific Institute to Collaborate on Research in Neurodegenerative Diseases

Merck Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Mu

Merck Serono: Enrollment Completed for ORACLE MS Study of Cladribine Tablets in Patients at Risk of Developing MS

Merck Serono: Ready-to-Use Formulation of Recombinant Growth Hormone Saizen Recommended for Approval in Europe

Merck Serono Announces Top-Line Results of Long-Term Study of Safinamide as Add-on Treatment to Levodopa in Advanced Parkinson's

Merck Serono Sells Théramex to Teva for EUR 265 Million

Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of

Merck Serono to Introduce RebiDose(TM), the Rebif(R) Single Use Pre-filled Pen for Treatment of Multiple Sclerosis

SRA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE